The Bladder Cancer Company Photocure ASA (OSE:PHO) reported on Tuesday that its partner Asieris Pharmaceuticals (SSE:688176) has announced its parent company, Jiangsu Yahong Meditech Co., Ltd, has received marketing authorization for Hexvix in China.

The National Medical Products Administration has issued a Drug Registration Certificate for APL-1706 (Hexaminolevulinate Hydrochloride for Intravesical Solution).

Hexvix is indicated for cystoscopy in patients with bladder cancer, including those with suspected or diagnosed conditions. This product enhances detection rates of bladder cancer when used with blue light cystoscopy, improving surgical outcomes and reducing recurrence rates. APL-1706 is designed to accumulate in tumour cells and fluoresce under specific light wavelengths, aiding in tumour detection. Despite marketing approval, sales will depend on the registration progress of blue light cystoscopes in China.